RxDoctor Payments DataLook up a doctor →

Loan Retchless, NP

Nurse Practitioner · Tacoma, WANPI 1295784262

Payments from drug & device makers

$21,470in general payments, 2019–2025

Across 909 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AstraZeneca$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Astellas Pharma US Inc$2K
  • Seagen Inc.$941
  • Pfizer$783
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$18,11784%
  • Education$1,6728%
  • Other$1,6818%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis68$2,566
AstraZeneca67$1,683
E.r. Squibb & Sons, L.L.C.85$1,594
Astellas Pharma US Inc61$1,552
Seagen Inc.43$941
Pfizer39$783
Lilly USA, LLC33$760
Merck30$684
Bristol Myers Squibb47$678
Amgen25$675
Pharmacyclics LLC, An Abbvie Company37$644
Incyte Corporation17$616
Bayer35$602
Johnson & Johnson(2 entities)27$515
Boehringer Ingelheim21$429
Stemline Therapeutics Inc.6$413
Daiichi Sankyo Inc.17$381
Taiho Oncology, Inc.17$374
ADC Therapeutics America, Inc.13$365
Regeneron Healthcare Solutions, Inc.16$312
GSK16$302
Beigene USA, Inc.19$301
Sobi, Inc7$300
Tersera Therapeutics LLC13$297
AbbVie11$295
Takeda Pharmaceuticals U.S.A., Inc.9$287
Beone Medicines USA, Inc.3$285
Gilead(2 entities)13$256
Genmab U.S., Inc.4$124
ADMA Biomanufacturing LLC5$122
Rigel Pharmaceuticals, Inc.5$107
Array Biopharma Inc4$106
Exelixis Inc.3$105
Apellis Pharmaceuticals, Inc.4$102
EMD Serono, Inc.5$101
Ipsen Biopharmaceuticals, Inc4$91
Acrotech Biopharma Inc.4$87
Eisai Inc.5$87
Myriad Genetic Laboratories, Inc.5$83
Morphosys, US Inc.4$82
Myovant Sciences Inc.4$81
Sanofi-aventis U.S. LLC1$78
Blueprint Medicines Corporation5$77
Sanofi4$76
Pharmacosmos Therapeutics Inc.4$76
G1 Therapeutics, Inc.3$69
AVEO Pharmaceuticals, Inc.4$68
TG Therapeutics, Inc.2$65
Genentech USA, Inc.3$65
Heron Therapeutics, Inc.3$63
Acceleron Pharma, Inc.3$59
Epizyme, Inc.1$51
Tempus AI, Inc1$50
Coherus Oncology, Inc.2$46
Puma Biotechnology, Inc.2$46
GE HealthCare2$45
Deciphera Pharmaceuticals Inc.2$40
Helsinn Therapeutics (U.S.), Inc.2$39
Mirati Therapeutics, Inc.2$36
Karyopharm Therapeutics Inc.1$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,470 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$226,198
Medicare patients
101
Services billed
8,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib19$306,889
RevlimidLenalidomide14$177,886
EliquisApixaban17$9,940
Letrozole31$407
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$311
Oxycodone Hcl23$250
Levothyroxine Sodium15$229
Gabapentin18$144
Lorazepam18$137
Anastrozole18$53
Alprazolam16$28
Metoprolol Tartrate24$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$644$306,88919 claims
Bristol Myers SquibbRevlimid$678$177,88614 claims
PfizerEliquis$783$9,94017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →